CN Patent

CN108239055B — 一种thr1442 l-天冬氨酸共晶、其制备方法及药物组合物

Assigned to Hangzhou Lingye Pharmaceutical Technology Co ltd · Expires 2023-07-18 · 3y expired

What this patent protects

本发明涉及SGLT2抑制剂THR1442(Bexagliflozin)和L‑天冬氨酸的共晶，与已知的THR1442二脯氨酸共晶相比，本发明的THR1442L‑天冬氨酸共晶具有一种或多种改进的特性。本发明还涉及THR1442L‑天冬氨酸共晶的制备方法、其药物组合物及其用于治疗受SGLT或SGLT2抑制之影响的疾病或病症的方法。

USPTO Abstract

本发明涉及SGLT2抑制剂THR1442(Bexagliflozin)和L‑天冬氨酸的共晶，与已知的THR1442二脯氨酸共晶相比，本发明的THR1442L‑天冬氨酸共晶具有一种或多种改进的特性。本发明还涉及THR1442L‑天冬氨酸共晶的制备方法、其药物组合物及其用于治疗受SGLT或SGLT2抑制之影响的疾病或病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN108239055B
Jurisdiction
CN
Classification
—
Expires
2023-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Lingye Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.